Literature DB >> 27617267

Osteosarcoma: mouse models, cell of origin and cancer stem cell.

Maria V Guijarro1.   

Abstract

Osteosarcoma (OS) is the most common non-hematologic primary tumor of bone in children and adults. High-dose cytotoxic chemotherapy and surgical resection have improved prognosis, with long-term survival for non-metastatic disease approaching 70%. However, most OS tumors are high grade and tend to rapidly develop pulmonary metastases. Despite clinical advances, patients with metastatic disease or relapse have a poor prognosis. Here the cell biology of OS is reviewed with a special emphasis on mouse models as well as the roles of the cell of origin and cancer stem cells. A better understanding of the molecular pathogenesis of human OS is essential for the development of improved prognostic and diagnostic markers as well as targeted therapies for both primary and metastatic OS.

Entities:  

Year:  2014        PMID: 27617267      PMCID: PMC5014233          DOI: 10.14304/surya.jpr.v2n2.3

Source DB:  PubMed          Journal:  Postdoc J        ISSN: 2328-9791


  91 in total

1.  Osteosarcoma as a second malignant neoplasm.

Authors:  Merlin R Hamre; Richard K Severson; Paul Chuba; David R Lucas; Ron L Thomas; Michael P Mott
Journal:  Radiother Oncol       Date:  2002-12       Impact factor: 6.280

Review 2.  Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors.

Authors:  Avery A Sandberg; Julia A Bridge
Journal:  Cancer Genet Cytogenet       Date:  2003-08

Review 3.  Regulation of osteoblast differentiation by transcription factors.

Authors:  Toshihisa Komori
Journal:  J Cell Biochem       Date:  2006-12-01       Impact factor: 4.429

4.  Mutation spectrum of the retinoblastoma gene in osteosarcomas.

Authors:  B Wadayama; J Toguchida; T Shimizu; K Ishizaki; M S Sasaki; Y Kotoura; T Yamamuro
Journal:  Cancer Res       Date:  1994-06-01       Impact factor: 12.701

5.  The differentiation stage of p53-Rb-deficient bone marrow mesenchymal stem cells imposes the phenotype of in vivo sarcoma development.

Authors:  R Rubio; I Gutierrez-Aranda; A I Sáez-Castillo; A Labarga; M Rosu-Myles; S Gonzalez-Garcia; M L Toribio; P Menendez; R Rodriguez
Journal:  Oncogene       Date:  2012-12-10       Impact factor: 9.867

6.  Rb regulates fate choice and lineage commitment in vivo.

Authors:  Eliezer Calo; Jose A Quintero-Estades; Paul S Danielian; Simona Nedelcu; Seth D Berman; Jacqueline A Lees
Journal:  Nature       Date:  2010-08-04       Impact factor: 49.962

7.  Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2.

Authors:  Alexander B Mohseny; Karoly Szuhai; Salvatore Romeo; Emilie P Buddingh; Inge Briaire-de Bruijn; Daniëlle de Jong; Melissa van Pel; Anne-Marie Cleton-Jansen; Pancras C W Hogendoorn
Journal:  J Pathol       Date:  2009-11       Impact factor: 7.996

8.  Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations.

Authors:  Stephanie Ma; Kwok Wah Chan; Terence Kin-Wah Lee; Kwan Ho Tang; Jana Yim-Hung Wo; Bo-Jian Zheng; Xin-Yuan Guan
Journal:  Mol Cancer Res       Date:  2008-07       Impact factor: 5.852

Review 9.  Cancer stem cells: impact, heterogeneity, and uncertainty.

Authors:  Jeffrey A Magee; Elena Piskounova; Sean J Morrison
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

10.  Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling.

Authors:  Christopher J Lengner; Heather A Steinman; James Gagnon; Thomas W Smith; Janet E Henderson; Barbara E Kream; Gary S Stein; Jane B Lian; Stephen N Jones
Journal:  J Cell Biol       Date:  2006-03-13       Impact factor: 10.539

View more
  1 in total

1.  Suppression of Estrogen Receptor Alpha Inhibits Cell Proliferation, Differentiation and Enhances the Chemosensitivity of P53-Positive U2OS Osteosarcoma Cell.

Authors:  Jir-You Wang; Chao-Ming Chen; Cheng-Fong Chen; Po-Kuei Wu; Wei-Ming Chen
Journal:  Int J Mol Sci       Date:  2021-10-18       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.